1. Lipsky BA. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 2006;20 Suppl 1:S68-77.
2. Lipsky BA., et. al. Diagnosis and Treatment of Diabetic Foot Infections Clin Infect Dis. 2006;39:885-910. Also available at www.idsociety.org/
3. Lipsky BA., et. al. Diagnosis and Treatment of Diabetic Foot Infections J Am Podiatr Med Assoc. 2005;95:183-210.
4. Embil J. Osteomyelitis: Debride Or Suppress?, Lecture, Diabetic Foot Global Conference (DFCON ‘05), March, 2005. Hollywood, Ca.
5. Jeffcoate WJ, Lipsky BA. Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. Clin Infect Dis. 2006 Aug 1;39 Suppl 2:S115-22.
6. Lipsky BA, Armstrong DG, et. al. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial. Lancet Nov 12 2005;366(9498):1695-1703.
7. Wieman TJ, Smiell JM, Sy Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998 May;21(5):822-7.
8. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs. 1998 Dec;56(6):1047-52.
9. Ge Y, MacDonald D, Henry MM, et. al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis. 1999 Sep;35(1):45-53.
10. Lipsky BA, Norden C, Itani K, and the Linezolid Diabetic Foot Infections Study Group. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2006;38:17-24.
11. Lipsky BA, Stoutenburgh U. Daptomycin for treating diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. Journal of Antimicrobial Chemotherapy 2005;55:240-5
12. Harkless L, Boghossian J, Pollak R, et. al. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt). 2005 Spring;6(1):27-40.
13. Ertapenem (for injection) prescribing information. Merck and Co, Inc. Whitehouse Station, NJ, October 2005.
14. Lipsky BA, Pecoraro RE, Wheat LJ. The diabetic foot: Soft tissue and bone infection. Infectious Diseases Clinic of North America 1990;4:409-432.
15. Shankar E M, Mohan V, Premalatha G, et. al. Bacterial etiology of diabetic foot infections in South India. Eur J Intern Med 2005;16: 567-70.
16. Chincholikar D A and Pal R B. Study of fungal and bacterial infections of the diabetic foot. Indian J Pathol Microbiol 2002;45: 15-22.
17. Viswanathan V, Jasmine J J, Snehalatha C, et. al. Prevalence of pathogens in diabetic foot infection in South Indian type 2 diabetic patients. J Assoc Physicians India 2002;50: 1013-6.
18. El-Tahawy A T. Bacteriology of diabetic foot. Saudi Med J 2000;21: 344-7
19. Graham DR, Ertapenem Once Daily Versus Piperacillin-Tazobactam 4 Times per Day for Treatment of Complicated Skin and Skin-Structure Infections in Adults: Results of a Prospective, Randomized, Double-Blind Multicenter Study. Clin Infect Dis. 2006;42:57-62.
20. Solomkin JS, et. al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg. 2003 Feb;237(2):235-45.
21. Park HK, et. al. Molecular analysis of colonized bacteria in a human newborn infant gut. J Microbiol. 2005 Aug;43(4):345-53.
22. Senneville E, et. al. Culture of Percutaneous Bone Biopsy Specimens for Diagnosis of Diabetic Foot Osteomyelitis: Concordance with Ulcer Swab Cultures. Clin Infect Dis. 2006;42:57-62.
23. Grayson ML, et. al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis. 1994 May;18(5):683-93.
24. Louie TJ, Bartlett JG, Tally FP, Gorbach SL. Aerobic and anaerobic bacteria in diabetic foot ulcers. Ann Intern Med. 1976 Oct;85(4):461-3.
25. Sapico FL, Witte JL, et. al. The infected foot of the diabetic patient: quantitative microbiology and analysis of clinical features. Rev Infect Dis 1984; 6 Suppl 1: S171-6.
26. LeFrock JL, Blais F, Schell RD, et. al. Cefotoxin in the treatment of diabetic patients with lower extremity infections. Infect Surg 1983; 2:361-374.
27. Lipsky BA, Pecoraro RE, et. al. Outpatient management of uncompliacted lower-extremity infections in diabetic patients. Arch Intern Med 1990 150 (4):790-7.
28. Bowler PG, Duerden BI, Armstrong DG. Wound Microbiology and Associated Approaches to Wound Managment. Clinical Microbiology Reviews. 2001;14(2):244-269.
29. Bowler PG. The anaerobic and aerboic microbiology of wounds: a review. Wounds. 1998; 10(6) 170-178.
30. Bowler PG, Davies BJ. The microbiology of acute and chronic wounds. Wounds. 1999; 11(4) 2-8.
31. Bessman AN, Sapico FL, Tabatabai M, Montgomerie JZ. Persistence of polymicrobial abscesses in the poorly controlled diabetic host. Diabetes. 1986 Apr;35(4):448-53.
32. Bessman AN, Geiger PJ, Canawati H. Prevalence of Corynebacteria in diabetic foot infections. Diabetes Care 1992 Nov;15(11):1531-3.
33. Bessman AN, Sapico FL. Infections in the diabetic patient: the role of immune dysfunction and pathogen virulence factors. J Diabetes Complications. 1992 Oct-Dec;6(4):258-62.
34. Dang, CN, Prasad YDM, Boulton AJM, Jude EB. Methicillin-Resistant Staphylococcus Aureus in the diabetic foot clininic: a worsening problem. Diabetic Med 2003; 20: 159-161.
35. Fridkin, SK, Hageman JC, Morrison M, et. al. Methicllin Resistant Staphylococcus aureus disease in three communities. NEJM April 7, 2005; 352:1436-1444.
36. Lipsky BA, Armstrong DG, Morgenstern DE, King TR, Abramson MA. Does a diabetic foot infection (DFI) wound score correlate with the clinical response to antibiotic treatment? Abstract O21. Diabetic Foot Study Group meeting of the EASD, Thessaloniki, Greece, September 9, 2005. (Oral) and Abstract 974, EASD, Athens, Greece, September 10, 2005.
37. Sheehan P, Lipsky BA,. Armstrong DG, Polis A, Morgenstern D. Dobbins T, Abramson M.A. Utility of Baseline Clinical Findings for the Prediction of Poor Outcomes of Diabetic Foot Infections (DFI): From the SIDESTEP Study Content Area. Abstract 354, IDSA meeting, San Francisco, October, 2005.
38. Citron, Goldstein EJC, Lipsky BA, Tice, A., Abramson, MA. Bacteriology of diabetic foot infections (DFI): 1647 Isolates from 473 specimens. Abstract 316, Infectious Diseases Society of America annual meeting, San Francisco, October 2005.
39. Citron DM, Goldstein EJC, Lipsky BA, Tice, A., Abramson, MA. Anaerobes isolated from intra-abdominal infections (IAI) versus diabetic foot infections (DFI): Differences in distribution & antimicrobial susceptibility. Abstract E-1440, Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 2005.
40. Armstrong DG, Lipsky BA, et al. Utility of dermal thermometry (DT) as an indicator of clinical cure in diabetic foot infection (DFI): a SIDESTEP substudy. Abstract OP1. Diabetic Foot Study Group meeting of the EASD, Thessaloniki, Greece, September 9, 2005.
41. Tice A., Turpin R, Wu J, et al. What are the economic advantages of a once-daily parenteral antibiotic? A cost analysis of the SIDESTEP study. 19th Annual Symposium on Advanced Wound Care (SAWC). May 1, 2006, San Antonio, Tx. |
